A study found that reducing the dose of pembrolizumab in patients with advanced stage non–small cell lung cancer did not ...
The event-free survival benefit with perioperative pembrolizumab in early NSCLC depends on the post-neoadjuvant residual ...
Data from a Phase 3 study has revealed that ivonescimab demonstrates a statistically significant and clinically meaningful ...
Summit Therapeutics stock rises 51% as ivonescimab shows promising results in lung cancer trial compared to Keytruda.
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.
Quaratusugene ozeplasmid is under clinical development by Genprex and currently in Phase II for Small-Cell Lung Cancer.
Summit Therapeutics Inc. (NASDAQ:SMMT) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab ...
IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.
Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback